Mechanism of action of IVIG and anti-D in ITP

Transfusion and Apheresis Science

Volumn 28, Issue 3, 2003, Pages 249-255

  Lazarus, Alan H ^a   Crow, Andrew R ^a  

^a CANADIAN BLOOD SERVICES   (Canada)

Author keywords

Anti D; Autoimmunity; Intravenous immunoglobulin; ITP; IVIG; Platelets; Thrombocytopenia

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; AUTOANTIBODY; CHEMOKINE; FC RECEPTOR; FIBRINOGEN RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2 4G2; MONOCLONAL RHESUS D ANTIBODY; NEUTRALIZING ANTIBODY; PHOSPHATASE; POLYCLONAL ANTIBODY; RECEPTOR SUBTYPE; RHESUS C ANTIBODY; RHESUS D ANTIBODY; RHESUS D ANTIGEN; SH2 CONTAINING INOSITOL 5 PHOSPHATASE; THROMBOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY COMPLEX; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B LYMPHOCYTE; CELL GROWTH; CELLULAR IMMUNITY; CLEARANCE; COMPETITIVE INHIBITION; CYTOKINE RELEASE; DISEASE MODEL; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; ERYTHROCYTE; GROWTH INHIBITION; HALF LIFE TIME; HELPER CELL; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LYMPHOCYTE FUNCTION; MONOCYTE; NONHUMAN; PHAGOCYTOSIS; RECEPTOR OCCUPANCY; REGULATORY MECHANISM; RETICULOENDOTHELIAL SYSTEM; REVIEW; SENSITIZATION; SIGNAL TRANSDUCTION; SPLENECTOMY; T LYMPHOCYTE; TARGET CELL; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE LIFESPAN;

EID: 0037410194     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-0502(03)00043-0     Document Type: Review

References (53)

1. Imbach P., Barandun S., d'Apuzzo V., Baumgartner C., Hirt A., Morell A.et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1:1981;1228-1231.
2. Salama A., Mueller-Eckhardt C., Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet. 2:1983;193-195.
3. Salama A., Kiefel V., Amberg R., Mueller-Eckhardt C. Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D)). Blut. 49:1984;29-35.
4. Choi C.W., Kim B.S., Seo J.H., Shin S.W., Kim Y.H., Kim J.S.et al. Response to high-dose intravenous immune globulin as a valuable factor predicting the effect of splenectomy in chronic idiopathic thrombocytopenic purpura patients. Am. J. Hematol. 66:2001;197-202.
5. Fehr J., Hofmann V., Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N. Engl. J. Med. 306:1982;1254-1258.
6. Bussel J.B., Kimberly R.P., Inman R.D., Schulman I., Cunningham-Rundles C., Cheung N.et al. Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood. 62:1983;480-486.
7. Uchida T., Yui T., Umezu H., Kariyone S. Prolongation of platelet survival in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. Thromb. Haemost. 51:1984;65-66.
8. Macintyre E.A., Linch D.C., Macey M.G., Newland A.C. Successful response to intravenous immunoglobulin in autoimmune haemolytic anaemia. Br. J. Haematol. 60:1985;387-388.
9. Newland A.C., Macey M.G. Immune thrombocytopenia and Fc receptor-mediated phagocyte function. Ann. Hematol. 69:1994;61-67.
10. Tovo P.A., Miniero R., Fiandino G., Saracco P., Messina M. Fc-depleted vs intact intravenous immunoglobulin in chronic ITP. J. Pediatr. 105:1984;676-677.
11. Burdach S.E., Evers K.G., Geursen R.G. Treatment of acute idiopathic thrombocytopenic purpura of childhood with intravenous immunoglobulin G: comparative efficacy of 7S and 5S preparations. J. Pediatr. 109:1986;770-775.
12. Crow A.R., Song S., Semple J.W., Freedman J., Lazarus A.H. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br. J. Haematol. 115:2001;679-686.
13. Ericson S.G., Coleman K.D., Wardwell K., Baker S., Fanger M.W., Guyre P.M.et al. Monoclonal antibody 197 (anti-Fc gamma RI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of Fc gamma RI on circulating monocytes. Br. J. Haematol. 92:1996;718-724.
14. Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 291:2001;484-486.
15. Clarkson S.B., Bussel J.B., Kimberly R.P., Valinsky J.E., Nachman R.L., Unkeless J.C. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N. Engl. J. Med. 314:1986;1236-1239.
16. Flesch B.K., Achtert G., Neppert J. Inhibition of monocyte and polymorphonuclear granulocyte immune phagocytosis by monoclonal antibodies specific for Fc gamma RI, II and III. Ann. Hematol. 74:1997;15-22.
17. Vossebeld P.J., Homburg C.H., Roos D., Verhoeven A.J. The anti-Fc gamma RIII mAb 3G8 induces neutrophil activation via a cooperative actin of Fc gamma RIIIb and Fc gamma RIIa. Int. J. Biochem. Cell Biol. 29:1997;465-473.
18. Kurlander R.J., Hall J. Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J. Clin. Invest. 77:1986;2010-2018.
19. Song S, Crow AR, Freedman J, Lazarus AH. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: An alternative to IVIG, Pre-published December 27, 2002; doi:10.1182/blood-2002-10-3078.
20. Teeling J.L., Jansen-Hendriks T., Kuijpers T.W., de Haas M., van de Winkel J.G., Hack C.E.et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood. 98:2001;1095-1099.
21. Lazarus A.H., Freedman J., Semple J.W. Intravenous immunoglobulin and anti-D in idiopathic thrombocytopenic purpura (ITP): mechanisms of action. Transfus. Sci. 19:1998;289-294.
22. Oksenhendler E., Bierling P., Brossard Y., Schenmetzler C., Girard P.M., Seligmann M.et al. Anti-RH immunoglobulin therapy for human immunodeficiency virus-related immune thrombocytopenic purpura. Blood. 71:1988;1499-1502.
23. Bussel J.B., Graziano J.N., Kimberly R.P., Pahwa S., Aledort L.M. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood. 77:1991;1884-1893.
24. Salama A., Kiefel V., Mueller-Eckhardt C. Effect of IgG anti-Rho (D) in adult patients with chronic autoimmune thrombocytopenia. Am. J. Hematol. 22:1986;241-250.
25. Cardo L.J., Strack M., Williams J. Anti-D for the treatment of splenectomized patients with immune thrombocytopenic purpura. Blood. 78:1991;2786-2787.
26. Scaradavou A., Woo B., Woloski B.M., Cunningham-Rundles S., Ettinger L.J., Aledort L.M.et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood. 89:1997;2689-2700.
27. Godeau B., Oksenhendler E., Brossard Y., Bartholeyns J., Leaute J.B., Duedari N.et al. Treatment of chronic autoimmune thrombocytopenic purpura with monoclonal anti-D. Transfusion. 36:1996;328-330.
28. Moise K.J. Jr., Cano L.E., Sala D.J. Resolution of severe thrombocytopenia in a pregnant patient with rhesus- negative blood with autoimmune thrombocytopenic purpura after intravenous rhesus immune globulin. Am. J. Obstet. Gynecol. 162:1990;1237-1238.
29. Crow A.R., Song S., Helgason C.D., Humphries R.K., Freedman J., Lazarus A.H. Reversal of murine passive-immune thrombocytopenia by IVIg requires Fc gamma RIIB expression but not the SH2-containing inositol-5-phosphatase SHIP. Blood. 98:2001;2169.
30. Takai T., Ono M., Hikida M., Ohmori H., Ravetch J.V. Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature. 379:1996;346-349.
31. Nakamura A., Yuasa T., Ujike A., Ono M., Nukiwa T., Ravetch J.V.et al. Fcgamma receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease. J. Exp. Med. 191:2000;899-906.
32. Ott V.L., Fong D.C., Cambier J.C. Fc gamma RIIB as a potential molecular target for intravenous gamma globulin therapy. J. Allergy Clin. Immunol. 108:2001;S95-S98.
33. Coggeshall K.M. Inhibitory signaling by B cell Fc gamma RIIb. Curr. Opin. Immunol. 10:1998;306-312.
34. Lin S.Y., Kinet J.P. Immunology. Giving inhibitory receptors a boost. Science. 291:2001;445-446.
35. Berchtold P., Dale G.L., Tani P., McMillan R. Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood. 74:1989;2414-2417.
36. Barbano G., Saleh M.N., Mori P.G., LoBuglio A.F., Shaw D.R. Effect of intravenous gammaglobulin on circulating and platelet-bound antibody in immune thrombocytopenia. Blood. 73:1989;662-665.
37. Boughton B.J., Cooke R.M., Smith N.A., Simpson A.W. Autoimmune thrombocytopenia: anti-glycoprotein IIb/IIIa auto antibodies are reduced after human anti-D immunoglobulin treatment. Autoimmunity. 18:1994;141-144.
38. Semple J.W., Kim M., Lazarus A.H., Freedman J. Gamma-globulins prepared from sera of multiparous women bind anti-HLA antibodies and inhibit an established in vivo human alloimmune response. Blood. 100:2002;1055-1059.
39. Delfraissy J.F., Tchernia G., Laurian Y., Wallon C., Galanaud P., Dormont J. Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Br. J. Haematol. 60:1985;315-322.
40. Dammacco F., Iodice G., Campobasso N. Treatment of adult patients with idiopathic thrombocytopenic purpura with intravenous immunoglobulin: effects on circulating T cell subsets and PWM-induced antibody synthesis in vitro. Br. J. Haematol. 62:1986;125-135.
41. Macey M.G., Newland A.C. CD4 and CD8 subpopulation changes during high dose intravenous immunoglobulin treatment. Br. J. Haematol. 76:1990;513-520.
42. Tsubakio T., Kurata Y., Katagiri S., Kanakura Y., Tamaki T., Kuyama J.et al. Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma-globulin therapy in patients with idiopathic thrombocytopenic purpura. Clin. Exp. Immunol. 53:1983;697-702.
43. Chiller J.M., Habicht G.S., Weigle W.O. Cellular sites of immunologic unresponsiveness. Proc. Natl. Acad. Sci. USA. 65:1970;551-556.
44. Andersson J.P., Andersson U.G. Human intravenous immunoglobulin modulates monokine production in vitro. Immunology. 71:1990;372-376.
45. Andersson U.G., Bjork L., Skansen-Saphir U., Andersson J.P. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology. 79:1993;211-216.
46. Aukrust P., Froland S.S., Liabakk N.B., Muller F., Nordoy I., Haug C.et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood. 84:1994;2136-2143.
47. Modiano J.F., Amran D., Lack G., Bradley K., Ball C., Domenico J.et al. Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobin. Clin. Immunol. Immunopathol. 83:1997;77-85.
48. Semple J.W., Allen D., Rutherford M., Woloski M., David M., Wakefield C.et al. Anti-D (WinRho SD) treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production. Am. J. Hematol. 69:2002;225-227.
49. Prasad N.K., Papoff G., Zeuner A., Bonnin E., Kazatchkine M.D., Ruberti G.et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J. Immunol. 161:1998;3781-3790.
50. Vuist W.M., Van Schaik I.N., Van Lint M., Brand A. The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids. J. Clin. Immunol. 17:1997;301-310.
51. Basta M., Langlois P.F., Marques M., Frank M.M., Fries L.F. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood. 74:1989;326-333.
52. Frank M.M., Miletic V.D., Jiang H. Immunoglobulin in the control of complement action. Immunol. Res. 22:2000;137-146.
53. Kekow J., Reinhold D., Pap T., Ansorge S. Intravenous immunoglobulins and transforming growth factor beta. Lancet. 351:1998;184-185.